⌘K
t
Roquefort Therapeutics plc issued a total of 900,000 warrants on 22 June 2022. Non-Executive Directors Ms Jean Duvall and Dr Simon Sinclair, along with Board Advisor Prof. Trevor Jones, each received 300,000 warrants as part of their annual remuneration package. These warrants have a 5-year term, an exercise price of 15 pence, with 50% exercisable after 12 months and the balance after 24 months.
| Date | 22 Jun 2022 |
| Time | 16:42:01 |
| Category | Capital structure |
| ID | 8571P |
22 June 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Issue of Warrants
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, announces the following issue of warrants to recently appointed Non-Executive Directors and an advisor to the Board:
|
Name |
Position |
Number of Warrants Issued |
Total Number of Warrants Held After Issue |
|
Ms Jean Duvall |
Non-Executive Director |
300,000 |
300,000 |
|
Dr Simon Sinclair1 |
Non-Executive Director |
300,000 |
300,000 |
|
Prof. Trevor Jones |
Board Advisor |
300,000 |
300,000 |
1 Warrants held in the name of Livingstone Investment Holdings Ltd, a company in which Dr Sinclair has a beneficial interest
The warrants have been issued in relation to the appointment of the abovenamed earlier this year and form part of their annual remuneration package.
The warrants have a term of 5 years and are exercisable at a price of 15 pence, with 50% exercisable after 12 months and the balance exercise after 24 months.
|
Roquefort Therapeutics plc |
|
|
Stephen West (Chairman) |
+44 (0)20 3290 9339
|
|
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale
Optiva Securities Limited (Broker) |
+44 (0)20 7466 5000 |
|
Christian Dennis |
+44 (0)20 3411 1881 |
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.
Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.
This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").
The notifications below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Jean Duvall |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non-Executive Director |
|
|
b) |
Initial notification /Amendment |
Initial |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Roquefort Therapeutics plc |
|
|
b) |
LEI |
254900P4SISIWOR9RH34 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Warrants (exercise price of 15 pence)
ISIN: GB00BMDQ2T15 |
|
|
b) |
Nature of the transaction |
Issue of warrants |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
15 pence per share |
300,000 |
|
|
d |
Aggregated information - Aggregated volume - Price |
- 300,000 - 15p |
|
|
e) |
Date of the transactions |
22 June 2022 |
|
|
f) |
Place of the transactions |
Outside a trading venue |
|
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Simon Sinclair |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non-Executive Director |
|
|
b) |
Initial notification /Amendment |
Initial |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Roquefort Therapeutics plc |
|
|
b) |
LEI |
254900P4SISIWOR9RH34 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Warrants (exercise price of 15 pence)
ISIN: GB00BMDQ2T15 |
|
|
b) |
Nature of the transaction |
Issue of warrants |
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
15 pence per share |
300,000 |
|
|
d |
Aggregated information - Aggregated volume - Price |
- 300,000 - 15p |
|
|
e) |
Date of the transactions |
22 June 2022 |
|
|
f) |
Place of the transactions |
Outside a trading venue |
|